The reported data demonstrated significantly different PON2 expression (tumor versus normal tissue) in patients who experienced disease relapse compared with those who had relapse-free survival, thus suggesting that the enzyme may have interesting predictive power for disease progression [41]. The gene discussed is PON2; the disease is neoplasm.